MLL
XFOR icon

Moody Lynn & Lieberson’s X4 Pharmaceuticals XFOR Stock Holding History

Moody Lynn & Lieberson’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-333
Closed -$17K – 238
2022
Q3 		$17K Hold
333
– – ﹤0.01% 215
2022
Q2 		$10K Hold
333
– – ﹤0.01% 218
2022
Q1 		$18K Hold
333
– – ﹤0.01% 227
2021
Q4 		$23K Buy
+333
New +$42.1K ﹤0.01% 234

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
TLP
Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
LCM
Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Moody Lynn & Lieberson's XFOR Position: Q4 2022 in Review

Moody Lynn & Lieberson sold out of X4 Pharmaceuticals (XFOR) in Q4 2022, closing a stake of 333 shares — an estimated $17K sold.

Moody Lynn & Lieberson first reported a position in XFOR in Q4 2021 and held it in 4 quarters. The position peaked at $23K in Q4 2021. 52 funds tracked by Wall St. Rank hold XFOR as of Q4 2022.

  • Moody Lynn & Lieberson reported no remaining X4 Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Moody Lynn & Lieberson sold 333 X4 Pharmaceuticals shares in Q4 2022, an estimated $17K.
  • Moody Lynn & Lieberson first reported a position in X4 Pharmaceuticals in Q4 2021 and held it in 4 quarters.
  • Moody Lynn & Lieberson's X4 Pharmaceuticals position peaked at $23K in Q4 2021.
  • 52 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q4 2022.

Based on Moody Lynn & Lieberson's 13F filing for Q4 2022, filed 1 Feb 2023.